Please login to the form below

Not currently logged in
Email:
Password:

ViiV boosted by positive phase III results for HIV drug Triumeq

Data reaffirms benefitsof drug in comparison to current antiretroviral medications 
ViiV Healthcare

Switching HIV patients to a once-daily version of Triumeq maintains viral suppression just as effectively as antiretroviral drugs, according to a new study.

The data posted by ViiV Healthcare, in which GlaxoSmithKline has a 75% stake, comes from the STRIIVING trial involving 551 patients.

The study compared safety, efficacy and tolerability of switching from an antiretroviral therapy to ViiV's once-daily fixed dose Triumeq (abacavir/dolutegravir/lamivudine) in adults with HIV-1 infection.

For both the group that switched to Triumeq and the group that remained on antiretroviral drugs, rates of viral suppression stood at 93% after 24 weeks.

John Pottage, chief scientific and medical officer at ViiV Healthcare, said: “For clinicians, choosing among antiretroviral therapies now involves balancing efficacy with factors such as tolerability, dosing, ability to use with other medications, and resistance profile.

“This data supports the use of once-daily abacavir/dolutegravir/lamivudine as a treatment option in the switch setting for appropriate patients.”

The STRIIVING study used patients who were initially on a wide range of protease inhibitors, integrase strand transfer inhibitors and non-nuceloside reverse transcriptase inhibitors thereby reflecting more common clinical situations.

As an additional positive for the drug, treatment satisfaction scores were significantly higher for patients switching to Triumeq compared to those who remained on their established regimen.

The current HIV fixed-dose combination market leader is by Gilead's Atripla (tenofovir, emtrcitabine and efavirenz), which in 2013 achieved sales of $3.6bn.

ViiV was set up in 2009 as a partnership between GSK and Pfizer, and Triumeq was granted approval in the US in August last year.

The value of the HIV treatment market is set to increase from $14bn in 2013 to well over $15bn by 2023 according to GlobalData. 

Article by
Nikhil Patel

23rd September 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics